AVROBIO, Inc., a leader in lentiviral-based gene therapies, is a clinical stage company developing disruptive therapies that have the potential to transform patients’ lives in a single dose.

Stock Quote

Press Releases
January 9, 2020
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 9, 2020-- AVROBIO (NASDAQ: AVRO) (the “Company”), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the Company has granted a non-statutory stock option to a new employee as
December 19, 2019
AVROBIO Announces First Patient Dosed Using plato™ Platform
Patient is the fourth dosed in Phase 2 trial of AVR-RD-01, an investigational gene therapy for Fabry disease plato is AVROBIO’s platform for worldwide gene therapy commercialization CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 19, 2019-- AVROBIO (NASDAQ: AVRO) (the “Company”), a leading clinical-stage